As debates over rising medicine costs escalate, a new analysis forecasts that the growth of prices in the U.S. for prescription drugs will range from 0 to 3 percent over the next five years. At the same time, drug makers will collectively register sales growth anywhere from 3 percent to 6 percent.

By 2023, U.S. spending is expected to top $600 billion, up from nearly $500 billion this year, although this is before factoring in the rebates and discounts that drug makers pay to pharmacy benefit managers to win favorable insurance coverage on lists of medicines called formularies.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy